Curated data on obesity and incretin drugs from Midgard Finance (midgardfinance.com), with diabetes, antibody-drug conjugates and immunology alongside. Ask for a drug's weight-loss results by dose and timepoint, joined to the trial that produced them; adverse-event rates with the raw counts they were checked against; week-by-week weight-loss curves digitised from the papers; trial designs by NCT number or trial name; and upcoming readouts, approvals and earnings across sponsors. Every efficacy figure carries the estimand it was reported on. The same trial reports different numbers under its treatment-policy and on-treatment (efficacy) analyses, so the server never collapses them into one headline, and a comparison comes with a warning when the estimands differ. Every result links to the midgardfinance.com page it came from, so an answer can cite its source. Read-only and free, with no account or sign-in. It serves only what midgardfinance.com already publishes: no per-drug sales figures and nothing about any person.
verification is carried through verbatim. It is the raw-count recomputation recorded when the row was extracted ("997/2481 active = 40.18%"), and it is what lets a caller see that the percentage was checked against the paper rather than copied from an abstract.endpoint_pct and its estimand alongside the curve, because the endpoint marker and the last plotted point are different quantities and the curve alone does not say which one a reader is looking at.
